{"url_path":"/sec/bbot/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1869105/0001193125-26-219829-index.html","accession_number":"0001193125-26-219829","cik":"0001869105","ticker":"BBOT","issuer_name":"BridgeBio Oncology Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1869105/0001193125-26-219829-index.html","primary_entity_key":"0001869105","primary_entity_name":"BridgeBio Oncology Therapeutics, Inc."},"word_count":76,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nDuring the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).\n\n \n\n98\n\n[Table of Contents](#toc_page)"}